Command Palette

Search for a command to run...

Clinical Trials · NCT02381288

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

TerminatedPhase 2Kisspeptin (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Takeda
Enrollment
17
Start date
Sep 2015
Locations
1 site, United States
Primary endpoint
Percent Change From Baseline in Average Serum Concentration (Cav) of Total ST After 6 Weeks of Dosing
View Kisspeptin compound reference